Table 1: A summary of
selected studies with different approaches to colon cancer.
Study |
Key inclusion criteria |
Treatment |
Outcomes |
Quasar |
Stage II |
Surgery + QT 5-FU + Folinic acid vs. Surgery + observation |
Overall survival: 3.6% vs. 3.1% |
Sacura |
Stage II |
Surgery + QT oral UFT
during 1 year vs. surgery + observation |
Ongoing |
Mosaic |
Stage III |
5-FLU + Leucovorin vs.
FOLFOX 4 |
DFS: 67.4% vs. 3.3% |
Haller, et al. [62] |
Stage III |
XELOX vs. 5-FU + Folinic acid |
Survival in 3 years: 70.9% vs. 66.7% |
DFS: Disease
Free Survival